Israel Englander Sesen Bio, Inc. Transaction History

Millennium Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.49 - $0.61 $88,030 - $109,588	-179,654 Reduced 14.79%	1,035,151 $631,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $0.93 $0 - $1.36 Million	-1,464,044 Reduced 54.65%	1,214,805 $516,000
Q2 2022 Aug 15, 2022	BUY	$0.38 - $0.89 $1.02 Million - $2.38 Million	2,678,849 New	2,678,849 $2.17 Million
Q1 2022 May 16, 2022	SELL	$0.58 - $0.86 $8,323 - $12,341	-14,350 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.73 - $1.28 $430,967 - $755,668	-590,366 Reduced 97.63%	14,350 $12,000
Q3 2021 Nov 15, 2021	SELL	$0.77 - $4.91 $888,405 - $5.67 Million	-1,153,774 Reduced 65.61%	604,716 $480,000
Q2 2021 Aug 16, 2021	BUY	$2.18 - $4.66 $291,234 - $622,548	133,594 Added 8.22%	1,758,490 $8.12 Million
Q1 2021 May 17, 2021	BUY	$1.3 - $3.24 $1.28 Million - $3.2 Million	987,926 Added 155.1%	1,624,896 $4.23 Million
Q4 2020 Feb 16, 2021	BUY	$1.01 - $1.77 $643,339 - $1.13 Million	636,970 New	636,970 $860,000
Q1 2020 May 14, 2020	SELL	$0.39 - $1.03 $39,591 - $104,562	-101,517 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.89 - $1.5 $90,350 - $152,275	101,517 New	101,517 $106,000
Q2 2019 Aug 14, 2019	SELL	$0.95 - $2.46 $42,215 - $109,315	-44,437 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$0.69 - $1.47 $728,267 - $1.55 Million	-1,055,460 Reduced 95.96%	44,437 $46,000
Q4 2018 Feb 14, 2019	BUY	$0.96 - $2.04 $259,068 - $550,520	269,863 Added 32.51%	1,099,897 $1.56 Million
Q3 2018 Nov 14, 2018	BUY	$1.54 - $2.38 $1.28 Million - $1.98 Million	830,034 New	830,034 $1.79 Million

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.